title: Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay.
abstract: Phosphoinositide-3-kinases are important targets for drug development because many proteins in the PI3 kinase signaling pathway are mutated, hyperactivated, or overexpressed in human cancers. Here, the authors coexpressed the human class Ia PI3 kinase p110alpha catalytic domain with an N-terminal His-tag and the p85alpha regulatory domain in Sf9 insect cells. The complex consisting of p110alpha and p85alpha was purified by nickel affinity chromatography. The authors established an adenosine triphosphate (ATP) depletion assay to measure the activity of p110alpha/p85alpha. The assay was optimized by testing different lipids as substrates, as well as various kinase and lipid concentrations. Furthermore, they analyzed autophosphorylation of p110alpha/p85alpha and determined the IC(50) for wortmannin, a known PI3 kinase inhibitor. The IC(50) for wortmannin was determined to be 7 nM. From a selection of substrates, phosphatidylinositol-4, 5-biphosphate turned out to be the best substrate at a concentration of 50 microM. p110alpha/p85alpha underwent autophosphorylation most prominently at the p85alpha subunit. However, in the presence of lipid substrate, the autophosphorylation was negligible. In parallel, a second assay format using the AlphaScreen technology was optimized to measure PI3 kinase activity. Both assay formats used should be suitable for high-throughput screening for the identification of PI3 kinase inhibitors.
authors.affiliation: KinaseDetect ApS, Odense, Denmark.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Boldyreff
authors.forename: Tine L
authors.initials: TL
authors.lastname: Rasmussen
authors.forename: Hans H
authors.initials: HH
authors.lastname: Jensen
authors.forename: Alexandre
authors.initials: A
authors.lastname: Cloutier
authors.forename: Lucille
authors.initials: L
authors.lastname: Beaudet
authors.forename: Philippe
authors.initials: P
authors.lastname: Roby
authors.forename: Olaf-Georg
authors.initials: OG
authors.lastname: Issinger
mesh_terms: D000255:Adenosine Triphosphate / Q000172:deficiency*; D000730:Androstadienes / Q000494:pharmacology; D001681:Biological Assay / Q000379:methods*; D058534:Class I Phosphatidylinositol 3-Kinases; D006801:Humans; D019869:Phosphatidylinositol 3-Kinases / Q000302:isolation & purification* / Q000378:metabolism*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation / Q000187:drug effects; D013997:Time Factors; D017186:Titrimetry; D000077191:Wortmannin
chemical_list: D000255:Adenosine Triphosphate; D000730:Androstadienes; D058534:Class I Phosphatidylinositol 3-Kinases; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000077191:Wortmannin; C497132:PIK3CB protein, human